bone morphogenetic protein 15Genealiases: GDF9B · ODG2 · POF4
Q-omics provides the consensus-scored BMP15 profile across patient tissues and cancer cell-line models. BMP15 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BMP15 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, BMP15 RNA expression shows 6,830 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight ACC, LUAD, and PCPG as cancer lineages where BMP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMP15 survival associations across molecular data types. BMP15 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMP15 RNA expression–survival associations across cancer types. High BMP15 expression shows unfavorable associations in ACC, DLBC, PAAD, BLCA, THCA and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for BMP15 RNA expression.
This table summarizes BMP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BMP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMP15 shows lower tumor expression in LUAD, LUSC, UCEC and KICH and higher tumor expression in KIRC. The LUAD box plot shows higher BMP15 RNA expression in normal versus tumor tissue (log2 FC = −0.137, t-test p < 0.001).
This table shows molecular features associated with BMP15 in patient tissues and cancer cell lines. In patient samples, BMP15 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, BMP15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
